Oragenics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.0001
- Today's High:
- $3.3
- Open Price:
- $3.09
- 52W Low:
- $2.6
- 52W High:
- $19.47
- Prev. Close:
- $3.2
- Volume:
- 4783
Company Statistics
- Market Cap.:
- $8.13 million
- Book Value:
- 2.798
- Revenue TTM:
- $116234
- Operating Margin TTM:
- -10513.12%
- Gross Profit TTM:
- $-9941163
- Profit Margin:
- 0%
- Return on Assets TTM:
- -56.72%
- Return on Equity TTM:
- -99.84%
Company Profile
Oragenics Inc had its IPO on 2004-02-25 under the ticker symbol OGEN.
The company operates in the Healthcare sector and Biotechnology industry. Oragenics Inc has a staff strength of 6 employees.
Stock update
Shares of Oragenics Inc opened at $3.09 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3 - $3.3, and closed at $3.19.
This is a -0.31% slip from the previous day's closing price.
A total volume of 4,783 shares were traded at the close of the day’s session.
In the last one week, shares of Oragenics Inc have slipped by -8.07%.
Oragenics Inc's Key Ratios
Oragenics Inc has a market cap of $8.13 million, indicating a price to book ratio of 1.7019 and a price to sales ratio of 91.269.
In the last 12-months Oragenics Inc’s revenue was $116234 with a gross profit of $-9941163 and an EBITDA of $-12171393. The EBITDA ratio measures Oragenics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Oragenics Inc’s operating margin was -10513.12% while its return on assets stood at -56.72% with a return of equity of -99.84%.
In Q2, Oragenics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 56.7%.
Oragenics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-6.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Oragenics Inc’s profitability.
Oragenics Inc stock is trading at a EV to sales ratio of 97.2917 and a EV to EBITDA ratio of -0.5216. Its price to sales ratio in the trailing 12-months stood at 91.269.
Oragenics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $8.46 million
- Total Liabilities
- $1.14 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Oragenics Inc ended 2024 with $8.46 million in total assets and $0 in total liabilities. Its intangible assets were valued at $8.46 million while shareholder equity stood at $7.26 million.
Oragenics Inc ended 2024 with $0 in deferred long-term liabilities, $1.14 million in other current liabilities, 2025.00 in common stock, $-191457940.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.47 million and cash and short-term investments were $6.47 million. The company’s total short-term debt was $190,242 while long-term debt stood at $0.
Oragenics Inc’s total current assets stands at $8.10 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $13163.00 compared to accounts payable of $590576.00 and inventory worth $0.
In 2024, Oragenics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Oragenics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.19
- 52-Week High
- $19.47
- 52-Week Low
- $2.6
- Analyst Target Price
- $90
Oragenics Inc stock is currently trading at $3.19 per share. It touched a 52-week high of $19.47 and a 52-week low of $19.47. Analysts tracking the stock have a 12-month average target price of $90.
Its 50-day moving average was $3.42 and 200-day moving average was $4.86 The short ratio stood at 1.49 indicating a short percent outstanding of 0%.
Around 194.2% of the company’s stock are held by insiders while 296.2% are held by institutions.
Frequently Asked Questions About Oragenics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company’s product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.